Cytori Therapeutics’ (CYTX) “Neutral” Rating Reiterated at B. Riley
Cytori Therapeutics Inc (NASDAQ:CYTX)‘s stock had its “neutral” rating reaffirmed by equities research analysts at B. Riley in a report released on Wednesday.
CYTX has been the topic of a number of other research reports. Zacks Investment Research raised Cytori Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, May 12th. ValuEngine lowered Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Maxim Group set a $5.00 target price on Cytori Therapeutics and gave the company a “buy” rating in a research note on Friday, August 11th.
Shares of Cytori Therapeutics (NASDAQ CYTX) traded down 3.3506% during trading on Wednesday, reaching $0.3276. The company had a trading volume of 453,676 shares. The firm’s market capitalization is $11.37 million. The firm’s 50 day moving average price is $0.72 and its 200 day moving average price is $1.17. Cytori Therapeutics has a 12 month low of $0.31 and a 12 month high of $2.29.
Cytori Therapeutics (NASDAQ:CYTX) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by $0.02. Cytori Therapeutics had a negative net margin of 450.34% and a negative return on equity of 202.62%. The company had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $2.23 million. During the same period in the previous year, the company posted ($0.43) EPS. Cytori Therapeutics’s quarterly revenue was down 18.2% compared to the same quarter last year. Equities analysts predict that Cytori Therapeutics will post ($0.60) EPS for the current year.
WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/08/16/cytori-therapeutics-cytx-neutral-rating-reaffirmed-at-b-riley-2.html.
Several hedge funds and other institutional investors have recently modified their holdings of CYTX. Vanguard Group Inc. raised its position in shares of Cytori Therapeutics by 81.9% in the second quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock worth $674,000 after buying an additional 275,653 shares in the last quarter. Perkins Capital Management Inc. raised its position in shares of Cytori Therapeutics by 99.0% in the second quarter. Perkins Capital Management Inc. now owns 874,896 shares of the biotechnology company’s stock worth $962,000 after buying an additional 435,217 shares in the last quarter. Creative Planning raised its position in shares of Cytori Therapeutics by 9,659.6% in the third quarter. Creative Planning now owns 78,077 shares of the biotechnology company’s stock worth $158,000 after buying an additional 77,277 shares in the last quarter. Finally, Cambridge Associates LLC MA ADV acquired a new position in shares of Cytori Therapeutics during the first quarter worth $852,000. 10.01% of the stock is currently owned by institutional investors.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.